Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

Sagres Discovery, Inc. researches and discovers oncology treatments. Its technology platform combines the biology of cancer formation in mouse models with the robustness of genomic technologies to enable discovery and clinical validation of human cancer genes. The company is headquartered in Davis, CA.

Novartis Vaccines & Diagnostics, Inc. manufactures and markets health care and nutritional products. The company was founded in 1986 and is headquartered in East Hanover, NJ.

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.

As of May 28, 2009, Avalon Pharmaceuticals, Inc. was acquired by Clinical Data, Inc. Avalon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cancer therapeutics using its proprietary AvalonRx technology in the United States. The company’s lead product candidate, AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, is in Phase IIa clinical development for the treatment of hematologic and solid cancers. Avalon Pharmaceuticals has drug discovery, development, and commercialization agreement with Merck & Co., Inc. to identify and develop inhibitors against a selected target in the area of oncology; a collaboration and license agreement with MedImmune, Inc. for the discovery of small molecule therapeutic compounds in the area of inflammatory disease; a collaboration agreement with ChemDiv, Inc. for the discovery and development of small molecule oncology therapeutics; a collaboration with Medarex, Inc. to jointly research, develop, and commercialize human antibodies against the company’s cancer targets; and an agreement with Novartis Institutes for Biomedical Research, Inc. for the discovery of small molecule therapeutic compounds. The company was incorporated in 1999 and is headquartered in Germantown, Maryland.

National University Corp. Tokyo Medical & Dental University is a private company headquartered in Japan that operates as an national educational institution for dentistry.

Quest Diagnostics Investments LLC, a subsidiary of Quest Diagnostics, Inc., is an American company specializing in medical laboratories.

Chiron Corporation (/ˈkaɪrɒn/ KY-ron) was an American multinational biotechnology firm based in Emeryville, California that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals, vaccines, and blood testing. Chiron's vaccines and blood testing units were combined to form Novartis Vaccines and Diagnostics, while Chiron BioPharmaceuticals was integrated into Novartis Pharmaceuticals. In 2014, Novartis completed the sale of its blood transfusion diagnostics unit to Grifols and announced agreements for the sale of its vaccines unit to GlaxoSmithKline.

The King Faisal Specialist Hospital and Research Centre (Arabic: مستشفى الملك فيصل التخصصي ومركز الأبحاث‎) (KFSH&RC) is tertiary referral hospital in Riyadh, the capital city of Saudi Arabia. As a tertiary referral hospital, it offers primary and highly specialized inpatient and outpatient medical care and participates in many clinical and research studies. It is consistently recognized as one of the nation's top hospital specializing in Oncology, Organ Transplantation, Cardiovascular Diseases, Neurosciences and Genetic Diseases. A large portion of the patient population are referrals from other hospitals from across Saudi Arabia as a whole and the surrounding regions. The hospital handles around 10,000 thousand outpatient visits each year and houses over 1,600 beds and has 28 health outreach centers. It has a staff of over 1,000 doctors with over 13,500 total employees of 67 different nationalities.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

Shangqiu Cancer Institute, established on 1997-08-01, Business scope includes biotechnology development.Development of new drugs for preventing and treating tumors.to promote.application.Production.Sales.***

LG Life Sciences Ltd. engages in the development, production and marketing medicine and fine chemicals. Its products include growth hormone products, arthritis medicine, diabetes medicine, cosmetic surgery products, hypertension treatment, synthetic medicinal raw materials, and pesticide raw material. The company was founded on August 1, 2002 and is headquartered in Seoul, South Korea.

NantOmics develops cloud-based molecular profiling tools that help guide cancer patients. It is a molecular diagnostics company, develops molecular profiling solutions that identify personalized treatment options for cancer patients and their providers at the point of care. It offers GPS Cancer test that provides a molecular profile of patient’s cancer to inform personalized treatment strategies to oncologists and OncoPlexDx Targeted Proteomic panel that provides quantitative protein biomarker information for multiple clinically relevant proteins yielding insights into the biology driving the growth of the patient’s cancer. Patrick Soon-Shiong founded NantOmics in 2012, with its headquarters in Culver City, California. NantOmics operates as a subsidiary of NantWorks.

FUJIFILM Corp. engages in the provision of imaging and information solutions. Its offers photography equipment, supplies and services, optical devices, healthcare, high-performance materials, graphic systems, recording media, and industrial products. The company was founded on October 2, 2006 and is headquartered in Tokyo, Japan.

TOMA Biosciences is a genomics company that provides physicians with information to optimize treatment for cancer patients. TOMA’s proprietary sequencing solution turns the latest next=generation sequencing (NGS) technology into a powerful digital tool to detect the most clinically meaningful changes in a patient’s tumor DNA. Physicians use this important data to optimize treatment for their patients. TOMA technology enables laboratories to uncover the DNA alterations in cancer cells to provide meaningful data for researchers and clinicians seeking the optimal treatment options for their patients. The company is a commercial-stage private venture-backed company headquartered in Foster City, California.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Jilin Jinuo Biological Engineering Co., Ltd., established on 2011-03-30, Business scope includes technology research and development of biochemical products;Extraction of marine bioactive substances,purification,Synthesis technology research and development;R&D and application of cell technology;R&D of industrial enzyme preparations;Manufacturing of bio-based materials;Chinese herbal medicine planting;Primary processing of edible agricultural products;Production of Chinese herbal extracts;Cellulose fiber raw material and fiber manufacturing;Sales of plastic products;Instrument sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Forensic identification service;Research and development of corn peptide and related products,Production,Sales;Production of primary agricultural by-products,Sales;Dietary fiber product development,Production,Sales;food production,Sales;beverage production,Sales;Research and development of biochemical reagents;Development and Utilization of Biomass Energy;chemical reagent(Free of Hazardous Chemicals),Hardware Miscellaneous,sporting goods,Office Supplies Sales;Medical device research and development,Production,Sales;Production of disinfection products,Sales(Free of Hazardous Chemicals);Cosmetic production,Sales(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).